QIAGEN Launches Enhanced QCI Interpret for High-Throughput NGS Labs

(IN BRIEF) QIAGEN has launched an upgraded version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), tailored for high-throughput next-generation sequencing (NGS) labs. The new release enhances performance metrics like turnaround time and diagnostic yield through features such as bulk variant assessment and co-occurring variant flagging. It supports labs transitioning to larger gene panels and higher testing volumes, leveraging advanced AI capabilities for improved workflow scalability. QCI Interpret, trusted globally with over 4 million NGS test cases analyzed, is pivotal in enhancing variant interpretation and reporting accuracy across oncology and hereditary diseases.

(PRESS RELEASE) VENLO, 14-Jun-2024 — /EuropaWire/ — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has unveiled the latest version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), designed to elevate performance in high-throughput, next-generation sequencing (NGS) laboratories. This new release introduces significant enhancements aimed at improving turnaround time, diagnostic yield, and the overall quality of results.

The updated QCI Interpret leverages advanced artificial intelligence capabilities, including AI-derived literature searches and phenotype-driven ranking, to deliver scalable workflow solutions. Key features of the release include bulk variant assessment, co-occurring variant flagging, enhanced multi-user functionality, and improved test management capabilities. These enhancements are tailored to meet the increasing demands of labs transitioning to larger gene panels and higher testing volumes.

Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights, highlighted the industry shift towards comprehensive gene panels and whole exome sequencing, necessitating robust interpretation solutions. “The latest QCI Interpret release enables labs to efficiently scale interpretation, identify relevant variants, and support clinical decisions with faster turnaround times,” he stated.

QCI Interpret, renowned as the most widely used clinical decision support software globally, processes over 850,000 clinical samples annually. It has analyzed over 4 million NGS patient test cases worldwide, enhancing variant interpretation and reporting accuracy across oncology and hereditary diseases. The platform’s reliability and efficiency make it a preferred choice for labs of all sizes, including decentralized facilities and national precision medicine programs.

For over two decades, QCI Interpret has combined QIAGEN’s expert curation with machine-powered AI to ensure high-confidence variant analysis and reporting. Recently certified under the European IVDR as a Class C Medical Device, QCI Interpret sets a new standard in diagnostic NGS interpretation platforms.

Learn more about QIAGEN’s latest QCI Interpret release at QIAGEN Digital Insights.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Media Contacts:

Domenica Martorana
Associate Director Global Investor Relations
Germany: +49 2103 29 11244
Mobile: +49 152 018 11244
domenica.martorana@qiagen.com

Alexandra Koenig
Investor Relations Coordinator
Germany: +49 2103 29 11709
Mobile: +49 152 018 11709
alexandra.koenig@qiagen.com

John Gilardi
Vice President
Head of Corporate Communications and Investor Relations
Germany: +49 2103 29 11711
Mobile: +49 152 018 11711
john.gilardi@qiagen.com

SOURCE: QIAGEN